No head-to-head trials have been conducted comparing the efficacy and persistence of injectable drugs, dimethyl furamate, and teriflunomide, all approved for the first-line treatment of MS. Thus, Dr Clara López-Caneda (Hospital Alvaro Cunqueiro, Spain) and colleagues conducted a retrospective observational study to evaluate the relative effectiveness and persistence of these drugs in a real-world setting.
Between early 2015 and early 2024, the researchers included 400 patients who started a first-line MS treatment (132 patients with MS were prescribed injectable drugs, 130 dimethyl furamate, and 138 teriflunomide). Clinical and radiological variables were compared. Efficacy was evaluated in terms of percentages of patients reaching NEDA-2 (i.e. absence of relapses and progression of disability) and NEDA-3 (i.e. NEDA-2 plus absence of new T2 lesions or Gd-enhancing lesions on brain MRI). Dropout was defined as DMT discontinuation for any reason for at least 6 months.
During the first year of treatment, 79.8% of participants had NEDA-2 and 59.9% NEDA-3. Teriflunomide was associated with the most favourable outcome, with 87.0% of users reaching NEDA-2, compared with 77,6% on injectable drugs and 73.8% on dimethyl furamate (P<0.05). The survival analysis yielded no differences between the treatments in reaching NEDA-2 (P=0.27) and NEDA-3 (P=0.95). Participants in injectable drugs had a higher dropout rate (62.12%), compared with dimethyl furamate (43.08%) and teriflunomide (40.58%) (P<0.001). Treatment persistence was higher with dimethyl furamate and lower with injectable drugs (P=0.01).
- López-Caneda C, et al. Persistence and effectiveness of moderate efficacy drugs in multiple sclerosis patients. Real world data. P382, ECTRIMS 2024, 17–20 October 2024, Copenhagen, Denmark.
Medical writing support was provided by Michiel Tent
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Tolebrutinib slows disability in non-relapsing secondary progressive MS Next Article
More comorbidity is associated with worse clinical outcomes in MS »
« Tolebrutinib slows disability in non-relapsing secondary progressive MS Next Article
More comorbidity is associated with worse clinical outcomes in MS »
Table of Contents: ECTRIMS 2024
Featured articles
Revised McDonald criteria allow earlier and more precise MS diagnosis
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Online First
Revised McDonald criteria allow earlier and more precise MS diagnosis
Blood markers predict MS progression
High depression genetic burden associated with MS disease activity
More comorbidity is associated with worse clinical outcomes in MS
First-line moderate-efficacy DMTs show similar efficacy
Tolebrutinib slows disability in non-relapsing secondary progressive MS
Frexalimab shows favourable safety and efficacy in OLE
Transfer of ocrelizumab into breastmilk is negligible
Ineffective response to EBV in MS not seen in similar diseases
Encouraging real-world results of AHSCT to treat aggressive MS
Tolebrutinib slows disability worsening in relapsing MS
High-dose simvastatin does not slow disability progression in SPMS
Gut microbiota modulates inflammation and cortical damage
Related Articles
August 18, 2021
No higher early MS relapse frequency after stopping ponesimod
September 25, 2024
More comorbidity is associated with worse clinical outcomes in MS
December 9, 2021
Ocrelizumab shows long-term benefits in primary progressive MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com